Biosergen publishes interim report for the third quarter 2021

Report this content

Tuesday, November 30, 2021: Biosergen AB (“Biosergen” or the “Company”) thereby publishes the interim report for the third quarter 2021. The interim report is available as an attached document and on the company website (

Biosergen AB was registered in February 2021. On April 16, 2021, the company acquired Biosergen AS with the subsidiary Select Pharma PTY LTD and formed the group with Biosergen AB as parent company. As the company is new there are no comparative figures.

Summary of the Interim Report for Q3 2021

Consolidated group revenue 2,709 TSEK
Consolidated group loss before depreciation -6,583 TSEK
Consolidated group loss before net financials -6,583 TSEK
Consolidated net result -6,729 TSEK
Consolidated earnings per share (EPS) -0.87 SEK

Highlights during Q3 2021

  • On August 31, 2021, Biosergen AB announced publication of the interim report for the second quarter 2021
  • On August 24, 2021, Biosergen AB announced that it has received positive feedback from the Australian regulatory authorities on the application to initiate a phase I study in Australia of the Company’s proprietary antifungal drug candidate BSG005. With the approval, Biosergen is ready to conduct its First in Man clinical trial with BSG005.
  • On August 19, 2021, Biosergen AB announced that it has appointed Tine Kold Olesen as COO. Tine Kold Olesen (MSc, MBA, PhD) has an impressive resume in international drug development.

Highlights after the period

There have been no highlights after the period.

The Financial report can be found on our website:

For further information about Biosergen, please contact:

Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470

Certified Adviser

Erik Penser Bank
Telefon: +46 8 463 8000

This information is such information that Biosergen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on November 30, 2021.


Biosergen is a No-Research-Development-Only biotechnology company that employs all its organisational and financials resources on the clinical development of BSG005. BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of preclinical studies. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care, while being completely free of the kidney toxicity hampering other drugs in its class. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen is granted orphan drug status for BSG005 in the United States and expects to file the NDA by the end of 2025.